Eisai shares soared 7.4 percent as the failure of Novo Nordisk's semaglutide to reduce Alzheimer's disease progression removed a "modest" or "perceived" overhang on Biogen, which developed and co-markets Leqembi with partner Eisai.
›
▸
Link: https://scores.sebi.gov.in